(Q39250670)

10 September 2017

title

Erythropoietin receptor expression and its relationship with trastuzumab response and resistance in HER2-positive breast cancer cells (English)

1 reference

10 September 2017

1 reference

1 reference

Chi Zhang

1

1 reference

10 September 2017

Xuening Duan

2

1 reference

10 September 2017

Ling Xu

3

1 reference

10 September 2017

Jingming Ye

4

1 reference

10 September 2017

Jianxin Zhao

5

1 reference

10 September 2017

Yinhua Liu

6

1 reference

10 September 2017

language of work or name

English

0 references

publication date

2 November 2012

1 reference

Breast Cancer Research and Treatment

10 September 2017

published in

1 reference

10 September 2017

volume

136

1 reference

10 September 2017

issue

3

1 reference

10 September 2017

page(s)

739-748

1 reference

https://scigraph.springernature.com/pub.10.1007/s10549-012-2316-x

10 September 2017

exact match

0 references

cites work

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2316-X

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2316-X

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2316-X

Trastuzumab--mechanism of action and use in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2316-X

Resistance to HER2-directed antibodies and tyrosine kinase inhibitors: mechanisms and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2316-X

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2316-X

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2316-X

Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2316-X

Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2316-X

Breast carcinoma with amplified HER2: a gene expression signature specific for trastuzumab resistance and poor prognosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2316-X

Erythropoietin after a century of research: younger than ever

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2316-X

EPO's alter ego: erythropoietin has multiple actions.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2316-X

Erythropoietin biology in cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2316-X

Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2316-X

Recombinant human erythropoietin antagonizes trastuzumab treatment of breast cancer cells via Jak2-mediated Src activation and PTEN inactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2316-X

RNA interference-mediated inhibition of erythropoietin receptor expression suppresses tumor growth and invasiveness in A2780 human ovarian carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2316-X

Erythropoietin and its receptor in breast cancer: correlation with steroid receptors and outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2316-X

Targeted near-infrared imaging of the erythropoietin receptor in human lung cancer xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2316-X

Recombinant human erythropoietin in combination with chemotherapy increases breast cancer metastasis in preclinical mouse models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2316-X

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2316-X

Survival and invasiveness of astrocytomas promoted by erythropoietin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2316-X

Erythropoietin-induced activation of the JAK2/STAT5, PI3K/Akt, and Ras/ERK pathways promotes malignant cell behavior in a modified breast cancer cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2316-X

The erythropoietin/erythropoietin receptor signaling pathway promotes growth and invasion abilities in human renal carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2316-X

Lack of functional erythropoietin receptors of cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2316-X

Erythropoietin receptor expression and correlation to tamoxifen response and prognosis in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2316-X

Randomized Phase III Trial of Weekly Compared With Every-3-Weeks Paclitaxel for Metastatic Breast Cancer, With Trastuzumab for all HER-2 Overexpressors and Random Assignment to Trastuzumab or Not in HER-2 Nonoverexpressors: Final Results of Cancer an

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10549-012-2316-X

10.1007/S10549-012-2316-X

21 January 2018

Identifiers

DOI

1 reference

10 September 2017

1 reference